Corcept Therapeutics Employee Directory
Biotechnology ResearchCalifornia, United States501-1000 Employees
Corcept Therapeutics is a biotechnology company focused on cortisol modulation, developing molecules that regulate cortisol activity at the glucocorticoid receptor. Over more than 25 years, the company has identified and advanced more than 1,000 selective proprietary cortisol modulators. In 2012, it achieved FDA approval of a cortisol receptor blocker—the first approved treatment for Cushing's syndrome. Today, the organization is pursuing more than 30 ongoing studies across endocrinology, oncology, metabolism, and neurology to explore the broader therapeutic potential of cortisol modulation. Based in Redwood City, California, the company operates within the biotechnology research sector, focusing on cortisol signaling as a basis for treating serious diseases. In 2026, Corcept announced plans to present new data from the pivotal ROSELLA Phase 3 trial of Lifyorli for platinum-resistant ovarian cancer at ASCO 2026.